Potential inhibitors of protease 3CLpro virus COVID-19: drug reposition
Open Access
- 1 April 2020
- journal article
- Published by Institute of Biochemistry in Biomedical Chemistry: Research and Methods
- Vol. 3 (1), e00124
- https://doi.org/10.18097/bmcrm00124
Abstract
Pneumonia caused by the COVID-19 virus has led to quick search of drugs that would able to block the spread of this virus. A standard way of drug development is a long process. One approach that can significantly accelerate drug development is drug reposition. In this study a virtual screening of the database of approved drugs has been used for search inhibitors against 3СLpro COVID-19, the main protease of COVID-19. Molecular docking, simulation of molecular dynamics and binding energy estimation by MM-GBSA method allowed to select several compounds for further experimental testing. The most promising drugs are the HIV protease inhibitor Indinavir, the inhibitor of protease hepatitis C Telaprevir, the antiulcer drug Dalargin, and the ErB receptor tyrosine kinase inhibitor NeratinibThis publication has 22 references indexed in Scilit:
- Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDSJournal of Medicinal Chemistry, 2016
- Novel insight into drug repositioning: Methylthiouracil as a case in pointPharmacological Research, 2015
- Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelinesDrug Discovery Today, 2013
- Cancer drug discovery by repurposing: teaching new tricks to old dogsTrends in Pharmacological Sciences, 2013
- Challenges and opportunities of drug repositioningTrends in Pharmacological Sciences, 2013
- Implementation and evaluation of a docking‐rescoring method using molecular footprint comparisonsJournal of Computational Chemistry, 2011
- The resurgence of covalent drugsNature Reviews Drug Discovery, 2011
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- Conservation of substrate specificities among coronavirus main proteasesJournal of General Virology, 2002
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996